secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001104659-22-114224
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune Q2 net loss $43.1M; CERPASS enrollment complete, cash runway extended into 2025
--------------------------------------------------------------------------------

- Net loss of $43.1M for Q2 FY2022 (vs $29.4M in Q2 FY2021); R&D expenses $28.8M.
- Completed enrollment in CERPASS trial (n=211) of RP1+Libtayo in CSCC; primary data expected H1 2023.
- Six-month data from first 75 patients in IGNYTE (RP1+Opdivo anti-PD1 failed melanoma) expected by year-end.
- Closed $200M term loan with Hercules Capital; cash and investments $371.8M as of Sep 30, 2022.
- Cash runway extended into 2025, covering commercial infrastructure and confirmatory trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465922114224/0001104659-22-114224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465922114224/tm2229523d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer